US FDA Wants To Know What Doctors Know About Abuse-Deterrent Opioids
Executive Summary
Healthcare professionals will be asked about their knowledge of abuse-deterrent opioid formulations along with their views on prescription drug promotions.
You may also be interested in...
Rx Drug Ads: New US FDA Studies Target Accelerated Approval Information
Upcoming research projects will look at presentation of FDA approval status, timing of disease awareness ads, and healthcare professional views.
US FDA Chief Gottlieb Envisions Tiered Mandates For Opioid Training System
Mandatory training could be reserved for physicians who want to prescribe opioids for longer-term use, as opposed to those who would prescribe recommended amounts in blister packs; evidence that blister packs would affect prescribing still is needed, however.
Addiction Recovery Medications' 'Stigma' Needs To Be Eliminated, Gottlieb Says
US FDA commissioner tells House committee that culture changes – and label changes – are among the actions the agency is pursuing to address the opioid crisis.